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Microfluidic‑assisted preparation 
of RGD‑decorated nanoparticles: 
exploring integrin‑facilitated 
uptake in cancer cell lines
Julio M. Rios De La Rosa1,6*, Alice Spadea1, Roberto Donno1,2, Enrique Lallana1, 
Yu Lu1, Sanyogitta Puri3, Patrick Caswell4, M. Jayne Lawrence1, Marianne Ashford5 & 
Nicola Tirelli1,2*
This study is about fine tuning the targeting capacity of peptide‑decorated nanoparticles to 
discriminate between cells that express different integrin make‑ups. Using microfluidic‑assisted 
nanoprecipitation, we have prepared poly(lactic acid‑co‑glycolic acid) (PLGA) nanoparticles with a 
PEGylated surface decorated with two different arginine‑glycine‑aspartic acid (RGD) peptides: one is 
cyclic (RGDFC) and has specific affinity towards αvβ3 integrin heterodimers; the other is linear (RGDSP) 
and is reported to bind equally αvβ3 and α5β1. We have then evaluated the nanoparticle internalization 
in two cell lines with a markedly different integrin fingerprint: ovarian carcinoma A2780 (almost no 
αvβ3, moderate in α5β1) and glioma U87MG (very high in αvβ3, moderate/high in α5β1). As expected, 
particles with cyclic RGD were heavily internalized by U87MG (proportional to the peptide content and 
abrogated by anti‑αvβ3) but not by A2780 (same as PEGylated particles). The linear peptide, on the 
other hand, did not differentiate between the cell lines, and the uptake increase vs. control particles 
was never higher than 50%, indicating a possible low and unselective affinity for various integrins. 
The strong preference of U87MG for cyclic (vs. linear) peptide‑decorated nanoparticles was shown in 
2D culture and further demonstrated in spheroids. Our results demonstrate that targeting specific 
integrin make‑ups is possible and may open the way to more precise treatment, but more efforts need 
to be devoted to a better understanding of the relation between RGD structure and their integrin‑
binding capacity.
Integrins are targetable receptors. They are transmembrane glycoproteins, which connect cell bodies to pericel-
lular structures and therefore are critical in cell–cell and cell-environment  interactions1. Structurally, they are 
heterodimeric proteins composed of non-covalently linked α and β  subunits2. To date 18α and 8β subunits, and 
24 different heterodimers have been reported in humans, with each heterodimer displaying unique binding 
properties, tissue distribution, and biological  functions1 ,3. Although integrins are virtually ubiquitous, their 
heterodimeric identity and level of expression are a physio-pathological signature, which has a specific relevance 
in  cancer4, e.g. in the formation of metastatic niches or in angiogenetic  processes5. Most studies have focused 
either on integrins in peritumoral environments, e.g. on endothelial cells (ECs), critical to (neo)angiogenesis, or 
on those directly present on tumor  cells6. It is now well known that αv-containing integrins are highly expressed 
in both scenarios, but poorly expressed on healthy  cells7. In particular, αvβ3 (e.g. in pro-tumoral ECs) is the 
most abundant integrin capable of regulating  angiogenesis8. Among other heterodimers, also α5β1 has been 
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clearly defined as a proangiogenic  factor9. Interestingly, integrins are not only signalling and adhesion mol-
ecules overexpressed in pathological conditions (and therefore targetable); they are also efficient internalizers, 
involved in all major routes of endo/phagocytosis and rapidly recycled. It must be noted, however, that the 
mechanisms of internalization and recycling can be heterodimer-specific. For example, αvβ3 integrin follows a 
rapid Rab4-dependent route from early endosomes to the plasma membrane, whilst α5β1 is trafficked back via 
Rab11-dependent recycling  endosomes10. This multiple nature of pathology marker, cell surface binder and 
internalizer has led to the development of integrin-targeted  therapies11 ,12. To this end, nanocarriers decorated 
with integrin ligands would enable an enhanced targeting efficiency via the combination of active targeting of 
integrin-overexpressing with passive, preferential (but not cell-specific) accumulation in tumoral masses, typical 
of  colloids13–15. Indeed in vivo and ex vivo studies of arginine-glycine-aspartic acid (RGD) peptide-decorated 
polymeric nanoparticles have demonstrated a significant contribution of both active and passive accumulation 
 mechanisms16. Numerous integrin ligands have been explored, e.g. by coating nanocarriers or polymers with the 
said recognition ligands or via the design of protein-drug  conjugates17. Out of all the integrin-targeting ligands, 
RGD-containing peptides and their mimetics are the most  popular18 and possibly the most versatile, also due to 
the availability of a variety of conjugation  techniques19. Over the last decade, attention has specifically focused 
on peptides capable of targeting two of the most overexpressed heterodimers in cancer, i.e. αvβ3 for glioblas-
toma or ovarian  cancers11 ,17,20, and α5β1 for ovarian and lung  cancers17,21, providing the means for the potential 
targeted delivery of classical chemotherapeutic  agents22–25, nucleic  acids26,27,  proteins28, imaging  agents29,30, or a 
combination of  these28,31,32 to malignant cells.
It must also be noted that parameters such as the length, organization and sequence of the peptide, as well as 
the amount of exposed RGD and the mode of its presentation, can heavily affect the recognition and selectivity 
towards different integrins and therefore ultimately the targeting efficiency of the  formulation19. To minimize 
these variables, in the present study we have adopted a microfluidics-based approach to the production of RGD-
decorated and PEGylated polymer nanoparticles, which ensures the highest reproducibility both in nanoparticle 
dimension and surface coverage. We have previously produced particles via nanoprecipitation of poly(lactic 
acid-co-glycolic acid) (PLGA) (biocompatible, biodegradable, FDA-approved  polymer33) from acetone into water 
in the presence of a PEGylated emulsifier (Pluronic F127)34. Herein, we have extended this approach to manufac-
ture fluorescent PLGA nanoparticles with a controlled surface density of RGD peptides, which was obtained by 
using appropriate ratios of RGD end-functionalized Pluronic and the non-functional (OH-terminated) Pluronic. 
Further, we have used a cyclic (RGDc) and a linear (RGDl) peptide to produce particles with the same peptide 
content and exposure but different affinity for integrin heterodimers. We have then studied the nanoparticle 
uptake in two tumoral cell lines—A2780 (ovarian cancer) and U87MG (glioblastoma)—characterized by a 
considerably different integrin profile (here focusing on the αvβ3/α5β1 difference). The study therefore tries to 
answer the question whether it is possible to obtain a selective cell uptake via matching integrin expression with 
the appropriate peptide(s) of the particle surface. We have done so by quantifying the uptake of a small library 
of nanoparticles (2 peptides, four surface densities each) and relating the integrin make-up of the two cell types, 
looking also at the mechanism of endocytosis and intracellular localization, and eventually confirming the results 
(for U87MG) on spheroids. It is probably necessary to add that, due to the size of this study, its results are dif-
ficult to extrapolate to other cell or other tumor types, therefore the conclusions we reach should be taken as a 
qualitative general point rather than a quantitative rule.
Materials and methods
Materials. RG502 poly(d,l-lactide-co-glycolide) (PLGA, Resomer) was obtained from Evonik (Wembley, 
UK). RG502 Resomer PLGA, acid terminated (PLGA-COOH), Pluronic F127, divinyl sulfone (DVS), QuantiPro 
BCA assay kit, phosphate buffered saline solution (PBS, 10 mM  PO43−, pH = 7.4, D8537), 4-(4,6-dimethoxy-1,3,5-
triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) and 5-(N-Ethyl-N-isopropyl)amiloride (EIPA) were 
purchased from Sigma-Aldrich (Gillingham, UK). d6-dimethylsulfoxide (d6-DMSO) was supplied by VWR 
(Lutterworth, UK). Dichloromethane (DCM), acetonitrile (HPLC grade), tetrahydrofuran (THF) and Lissamine 
Rhodamine B ethylenediamine were from Fisher Scientific (Loughborough, UK). Sterile 2 mL round-bottom 
plastic tubes (#022363352) were acquired from Eppendor, UK. Arginine-glycine-aspartic acid (RGD) peptides: 
linear Ac-GCG YGR GDSPG-NH2 (purity > 99%, salt form: acetate salt) and cyclo(RGDFC) (purity > 99%, ace-
tate content: 2.98%, TFA content: 0.43%) were obtained from Biomatik (Wilmington, USA). The human ovar-
ian carcinoma A2780 (#93112519) and U87MG glioma (HTB-14) cell lines were acquired from Sigma-Aldrich 
(Gillingham, UK) and ATCC (Manassas, VA, USA), respectively. The RPMI 1640 (R0883) and MEM (51412C) 
cell culture media, Foetal Bovine Serum (FBS, F7524), L-Glutamine (G7513), Penicilin-Streptomycin (P4333) 
and Trypsin/EDTA (59417C) were all supplied by Sigma-Aldrich (Gillingham, UK). Costar polystyrene 12-well 
and 96-well plates with flat bottom, and 96-well ultra-low adherent (ULA) plates were bought from Corning, 
UK. The αvβ3 (mAb 1976, clone LM604) and α5β1 (mAb 13) blocking antibodies were acquired from EMD Milli-
pore, UK. The ibidi 8 well µ-Slides and LifeAct-TagGFP2 Protein were purchased from Ibidi GmbH (Germany). 
Green labelled-dextran, 70 kDa (#D7173), CellMask Green Plasma Membrane Stain (C37608), Hoechst 33342 
(H1399) were all acquired from Thermo Fisher Scientific (Loughborough, UK). CellTiter 96 Aqueous One Solu-
tion Cell Proliferation Assay (MTS) was purchased from Promega (Southampton, UK).
Preparation of Pluronic‑α,[[ω]]‑divinylsulfone (Pluronic‑VS). Pluronic F127 (20  g, 3.2  mmol of 
OH) was dissolved in toluene (100 mL) in a three neck round bottom flask connected to a Soxhlet (filled with dry 
4 Å molecular sieves) and fitted with a reflux condenser, under dry argon atmosphere and dried by azeotropic 
distillation (4 h). The dried Pluronic F127 was cooled to 40 °C and NaH (15.36 mg, 0.64 mmol, corresponding 
to 1:0.2 Pluronic F127-OH/NaH molar ratio) added. The reaction was stirred at 40 °C for 40 min. The partially 
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deprotonated Pluronic F127 was syphoned into another degassed reactor containing DVS (4.73 g, 40 mmol, 
corresponding to 80 mmol of double bonds, i.e. to 1:0.2:25 Pluronic F127-OH/NaH/double bonds molar ratio) 
previously dissolved in dry toluene (300 mL). The reaction was left stirring at 40 °C for 24 h. The mixture was 
filtered to remove any salt formed, neutralized by adding a drop of acetic acid, reduced in volume by rotary 
evaporation and precipitated twice in ice-cold diethyl ether. After precipitation, the polymer was washed three 
times with diethyl ether, dried under vacuum and stored at − 20 °C. Yield: 92% (based on the weight of recov-
ered polymer/theoretical amount of polymer). Conversion: 63% (molar percentage of reacted OH groups), as 
confirmed by 1H NMR.
1H NMR was recorded on ca. 1% wt. polymer solutions in  CDCl3,  D2O or  D2O/buffer mixture using a Bruker 
Avance 400 MHz spectrometer. The residual solvent signal was used as internal reference (ppm). NMR samples 
with a high content of non-deuterated aqueous solvent were analyzed using a pulse sequence with f1 presatura-
tion for the selective suppression of the HOD signal.
VS-Terminated Pluronic F127 (Pluronic-VS):  CDCl3, δ (ppm): 1.06–1.16 (m, methyl group in propylene oxide 
units, ≈ 311H); 3.23 (t, Hd, 4H); 3.28–3.82 (m, methylene and methine groups in both ethylene and propylene 
units, ≈1721H); 3.87 (t, He, 4H); 6.06 (d, Ha, 2H); 6.37 (d, Hb, 2H); 6.79 (dd, Hc, 2H). For proton numbering, 
please refer to Fig. 1B.
Preparation of Pluronic‑VS‑RGD conjugates. Peptide solutions were prepared in phosphate buffer 
(100 mM, pH = 9), previously degassed with argon, as follow: 21.5 mg and 11.6 mg of, respectively, linear and 
cyclic peptide (corresponding to ≈ 20  µmol of peptide) were dissolved in 1  mL of buffer. The pH was then 
adjusted to ≈ 9 using a 0.1 M NaOH solution and then both peptide solution volumes adjusted to 2.5 mL. Equal 
volumes of peptide solution and Pluronic F127-VS solution (10% w/v in phosphate buffer, pH = 9) were then 
mixed (30 min under stirring) in order to have a VS:peptide molar ratio of 1:2 (10 µmol of VS : 20 µmol of pep-
tide. 100 mg of Pluronic = 8 µmol of Pluronic F127 and 16 µmol of OH end groups. The 63% of OH group, cor-
responding to 10 µmol of VS, were replaced with VS group). Finally, the compound was dialyzed for a minimum 
of 12 h against MilliQ water using a Spectra-Por Float-A-Lyzer G2 (MWCO: 3.5 KDa, Spectrum Labs), freeze 
dried and stored at − 20 °C until further use.
Cyclo(RGDFC) (RGDc),  D2O, δ (ppm): 1.46–1.84 (m, H15 and H14a, 3H); 1.84–2.04 (m, H14b, 1H); 2.55 
(dd, H6a, 1H), 2.67 (dd, H6b, 1H); 2.72 (dd, H13a, 1H); 2.78 (dd, H13b, 1H); 3.06 (dd, H7a, 1H); 3.13 (dd, H7b, 
1H); 3.18–3.31 (m, H16, 2H), 3.52 (d, H2a, 1H); 4.21 (dd, H5, 1H); 4.25 (d, H2b, 1H); 4.43 (dd, H1, 1H); 4.67 
(dd, H4, 1H); 4.71 (dd, H3, 1H); 7.26–7.47 (m, H8, H9, H10, H11 and H12, 5H). For proton numbering, please 
refer to Fig. 1A.
Ac-GCG YGR GDSPG-NH2 (RGDl),  D2O, δ (ppm): 1.58–1.74 (m, H17 and H18, 4H); 1.74–1.88 (m, H23a, 1H); 
1.88–2.18 (m, H22a and H23b, 2H); 2.07 (s, acetyl, 3H); 2.24–2.44 (m, H22b, 1H); 2.67 (dd, H20a, 1H); 2.73 
(dd, H20b, 1H); 2.87–2.97 (m, H11, 2H); 2.99 (dd, H12a, 1H); 3.13 (dd, H12b, 1H); 3.24 (t; H19, 2H); 3.70–4.06 
(m, H24, H21, H1, H3, H5, H7 and H11, 14H); 4.40 (dd, H6, 1H); 4.45 (dd, H10, 1H); 4.55 (dd, H2, 1H); 4.60 
(dd, H4, 1H); 4.69 (dd, H8, 1H); 4.78 (dd, H9, 1H);6.87 (d, H14 and H15, 2H); 7.15 (d, H13 and H16, 2H). For 
proton numbering, please refer to Fig. 1A.
Pluronic F127-RGDc,  D2O, δ (ppm): 1.20 (d, methyl group in propylene oxide units, ≈ 312H); 1.48–1.81 (m, 
H15 and H14a, 6H); 1.85–1.99 (m, H14b, 2H); 2.56 (dd, H6a, 2H); 2.68 (dd, H6b, 2H); 2.78–2.93 (m, H13, 4H); 
3.06 (dd, H7a, 2H); 3.13 (dd, H7b, 2H); 3.17–3.31 (m, H16, 4H); 3.31–3.99 (m, H2a, Ha-e (proximal to sulfone), 
methylene and methine groups in both ethylene and propylene units, ≈ 1802H); 4.01 (t, H20, 4H); 4.21–4.31 
(m, H2b, H5, 6H); 4.42 (dd, H1, 2H); 4.67 (dd, H4, 2H); 4.71 (dd, H3, 2H); 7.27–7.49 (m, H8, H9, H10, H11 and 
H12, 10H). For proton numbering, please refer to Fig. 1A, B.
Pluronic F127-RGDl,  D2O, δ (ppm): 1.20 (d, methyl group in propylene oxide units, ≈ 266H); 1.53–1.75 (m, 
H17 and H18, 8H); 1.75–1.88 (m, H23a, 2H); 1.88–2.18 (m, H22a and H23b, 4H); 2.07 (s, acetyl, 6H); 2.26–2.44 
(m, H22b, 2H); 2.66 (dd, H20a, 2H); 2.71 (dd, H20b, 2H); 2.93–3.05 (m, H11, 4H); 3.09 (dd, H12b, 2H); 3.14 
(dd, H12b, 2H); 3.25 (t, H19, 4H); 3.33–4.06 (m, H24, H21, H1, H3, H5, H7, H11, Ha-e (proximal to sulfone), 
methylene and methine groups in both ethylene and propylene units, ≈ 1560H); 4.40 (dd, H6, 2H); 4.46 (dd, 
H10, 2H); 4.56–4.64 (m, H2 and H4, 4H); 4.68 (dd, H8, 2H); 4.75–4.79 (m, H9, 2H); 6.88 d (d, H14 and H15, 
4H); 7.16 (d, H13 and H16, 4H). For proton numbering, please refer to Fig. 1A, B.
Preparation of fluorescently labelled PLGA (PLGA‑Rho). PLGA-COOH was covalently conjugated 
to Lissamine Rhodamine B ethylenediamine to produce a fluorescently labeled PLGA (PLGA-Rho). All solutions 
were prepared in THF unless stated otherwise. Briefly, 50 mg of the polymer, PLGA-COOH (4.17 × 10−3 mmol 
of carboxylate) was dissolved in 10 mL by shaking overnight. After complete dissolution of the polymer, 2.5 mL 
of a solution containing 3.25 mg of rhodamine B (5.4 × 10−3 mmol, 1.3 eq.) was added to the polymer solution 
and stirred for 15 min, after which 2.5 mL of a solution containing 7 mg of DMT-MM (2.5 × 10−2 mmol, 6 eq.) 
was added. The reaction was stirred at 400 rpm at 25 °C for 72 h, and then quenched and precipitated using cold 
methanol. The polymer pellet was collected by centrifugation (10 min at 4,500 g), resuspended in dichlorometh-
ane, and precipitated again using cold methanol. The precipitate was then thoroughly washed with methanol and 
finally vacuum-dried (mass recovery: 80%). The degree of derivatization (0.8% mol) was determined by measur-
ing the fluorescence intensity of the PLGA-Rho, using the rhodamine dye to relate the measured emission to the 
molar concentrations of the fluorophore (please note that this was later transformed in a molar ratio between 
functionalized and non-functionalized units in the polymer).
Microfluidics‑assisted nanoprecipitation. An automated microfluidic Asia 320 flow reactor (Syrris, 
Royston UK) was used for all nanoparticle preparations. Nanoparticles were prepared by mixing a 0.015%wt. 
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aqueous surfactant solution (Pluronic F127 mixtures containing 0, 1, 10, 50 or 100% of RGD derivatives) with 
a 0.31%wt. PLGA (RG502) acetone solution using an Asia 1,000 μL 3-input reaction chip (Syrris part number: 
2100146). For fluorescently labelled particles, the acetone solution contained a 10% wt. PLGA-Rho:PLGA mix-
tures. In all experiments acetone/water flow rate ratio of 0.2 and a total flow of 2 mL/min. Nanoparticles were 
left at 30 °C for 12 h under stirring in order to evaporate the acetone, filtered through a 0.22 µm PES membrane, 
divided in 1 mL aliquots and centrifuged in sterile 2 mL round-bottom plastic tubes. Particles were then resus-
pended in 1 mL of distilled water; five of these aliquots were combined and freeze dried to determine the dry 
weight and from there the mass recovery of the process. Typical mass recovery values: 90–95%. For cell culture 
purposes, the nanoparticles were further centrifuged and re-dispersed in culture media, typically at a concentra-
tion of 0.5 mg/mL.
Figure 1.  Pluronic F127-VS-RGD preparation and characterization. (A) Two-step reaction scheme and 
structure of the two thiol-containing RGD peptides. Numbers in red provide the assignment of the resonances 
in 1H NMR spectra (see experimental part). (B) 1H NMR spectra of Pluronic F127 (black) and Pluronic 
F127-VS (red) show the presence of vinylic unsaturations in PEG-VS. (C) Magnification of the 1H NMR spectra 
of Pluronic F127-VS and of its reaction products with either linear (RGDl) or cyclic (RGDc) peptide. The 1H 
NMR analysis confirmed complete conversion of Pluronic F127-VS: no trace of the vinyl groups (blue signals) 
was detected in the reaction mixture after a reaction time of 30 min. The red and green peaks are related to the 
presence of aromatic protons on the side chains of tyrosine (RGDl) and phenylalanine (RGDc), respectively.
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Nanoparticle characterization. Dynamic light scattering (DLS). The Z-average (apparent hydrody-
namic) size, polydispersity (PDI), count rates and ζ-potential of nanoparticle dispersions were obtained by DLS/
electrophoretic mobility measurements at 25˚C using a Zetasizer Nano ZS (Malvern Instrument, UK). Samples 
were measured as prepared immediately after evaporating the organic phase.
Fluorimetry. A Synergy 2 multi-mode Biotek microplate reader (NorthStar Scientific Ltd, Leeds, UK) equipped 
with Gen5 software was used to characterize the fluorescence intensity of the nanoparticles prepared using dif-
ferent PLGA-Rho blends (excitation: 540/25 nm; emission: 620/40 nm; optical position: top 50%, light source: 
xenon flash).
Quantification of RGD nanoparticle coverages. The QuantiPro bicinchoninic acid (BCA) Assay Kit was used 
to assess the amount of RGD exposed at the surface of the RGD-functionalized PLGA nanoparticles. Briefly, 
nanoparticles (prepared from 0, 1, 10, 50 or 100% Pluronic F127-RGD mixtures) were centrifuged at 13,000 rpm 
for 15 min, concentrated 5 to 10 times (i.e. concentration range 5–10 mg/mL), and washed with distilled water 
(three steps of centrifugation/washings to ensure removal of unbound RGD-surfactant) before being incubated 
with the BCA solution overnight at 37  °C, following manufacturer recommendations for highest sensitivity. 
Prior to any measurements, each nanoparticle suspension was thoroughly centrifuged (at 13,000 rpm for 1 h 
at 4 °C) to eliminate any background contribution to the UV–Vis reading from light scattering of the particles. 
Finally, the amount of RGD peptide at the surface of the nanoparticles was estimated by using a calibration of 
soluble Pluronic F127-RGDx (linear or cyclic RGD peptides as appropriate) in water in the concentration range 
0.12–125 µg/mL using a Synergy2 Biotek plate reader (excitation: 540/25 nm; emission: 620/40 nm) equipped 
with Gen5 software (sensitivity of the instrument adjusted to wells with the highest nanoparticle concentration 
of the calibration curve; optical position: top 50%; light source: xenon flash). Note that in this quantification we 
assumed an identical BCA assay response for both the Pluronic F127-RGD (“calibration curve standard”) and 
the RGD-functionalized nanoparticles (“sample”).
Cell experiments. General cell culture. A2780 and U87MG cells were grown in MEM or RPMI 1640 re-
spectively under standard conditions (5% (v/v)  CO2, 37 °C), regularly tested for mycoplasma, and used at pas-
sage numbers below 20. The RPMI 1640 and MEM cell culture growth media were supplemented with 10% (v/v) 
FBS, 2 mM L-glutamine, and 1% (v/v) penicilin-streptomycin.
Nanoparticle uptake studies (flow cytometry). U87MG and A2780 cells were seeded in Costar polystyrene 
12-well plates with flat bottom at a density of 1.5 × 104 and 3 × 104 cells/cm2, respectively. Cells were left to adhere 
overnight and grow until a confluency of ~ 60 to 70% was reached. Cells were then exposed to 0.5  mg/mL 
rhodamine-labelled PLGA nanoparticles (centrifuged and redispersed in the appropriate cell culture medium) 
differing in (1) the format of RGD peptide exposed at their surface, i.e. either RGDc or RGDl, or (2) the amount 
of RGD peptide exposed at their surface, i.e. 1, 10, 50 or 100% Pluronic F127-RGD/–OH mixtures, for specific 
time points (4 , 8 and 16 h) in a humidified 5% (v/v)  CO2 air atmosphere at 37 °C. A control of nontargeted 
particles, i.e. particles with exposed –OH end groups on their surface was also studied. Following a protocol pre-
viously described by our  group35, the media were removed, the cells washed with PBS, detached by incubation 
with trypsin/EDTA (59417C, Sigma-Aldrich, UK) for 10 min at room temperature, and finally resuspended in 
400 µL PBS per vial. The internalization of rhodamine labelled PLGA particles was determined on 10,000 live, 
individual cells with a BD LSRFortessa cytometer (BD Bioscience, San Jose CA, USA) equipped with FACSDiva 
software (v8.0.1). Data were analyzed with FlowJo (vX.0.7, Tree Star, Ashland, OR, USA) after gating single and 
live events in the FSC-A/FSC-H and FSC/SSC windows, respectively. Untreated cells were used as autofluores-
cence control in order to calculate any change in the median fluorescence intensity (MFI) over time, as well as 
the percentage of positive events for each cell line.
Selective inhibition of cell uptake pathways (U87MG cell line). Flow cytometry. U87MG cells were plated in 
Costar polystyrene 12-well plates with flat bottom at a density of 1.5 × 104 cells/cm2. Cells were left to attach and 
grow until a confluency of ~ 60 to 70% was reached. In order to block specific uptake pathways, cells were pre-
treated for 30 min at 37 °C with growth medium containing either (1) EIPA 5 µM, (2) 5 µg/mL αvβ3 antibody, (3) 
5 µg/mL α5β1 antibody, (4) excess RGDc peptide 2.5 µM, (5) excess RGDl peptide 2.5 µM, or (6) PBS. Following 
pre-treatment and a thorough washing with PBS, the cells were exposed to rhodamine labelled PLGA particles 
(nontargeted or functionalized either with 100% RGDc or RGDl mixtures) in cell media containing the afore-
mentioned inhibitors/competitors for 1 h at 37 °C. A control at 4 °C was also run to evaluate the effect of block-
ing the energy dependent processes on nanoparticle uptake. Following a previously described  protocol35, the 
media were removed, the cells washed with PBS, detached by incubation with trypsin/EDTA (59417C, Sigma-
Aldrich, UK) for 10 min at room temperature and finally resuspended in 400 µL PBS per vial. The internaliza-
tion of rhodamine labelled nanoparticles was determined on 10,000 live, individual cells with a BD LSRFortessa 
cytometer (BD Bioscience, San Jose CA, USA) equipped with FACSDiva software (v8.0.1). Data were analyzed 
with FlowJo (vX.0.7, Tree Star, Ashland, OR, USA) after gating single and live events in the FSC-A/FSC-H and 
FSC/SSC windows, respectively. Untreated cells (negative control) were used during acquisition as autofluores-
cence control as well as to threshold the percentage of positive events for time point. Data were normalized to 
the positive control (cells pre-treated with PBS).
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Confocal microscopy. U87MG cells were seeded with a density of 25,000 cells/cm2 in an Ibidi 8 well µ-Slide 
and let to attach overnight at 37 °C, 5%  CO2. A volume of 200 µL/well of cell culture media containing 0.5 mg/
mL of rhodamine-labelled particles (prepared from Pluronic F127-RGD 0% (i.e. nontargeted) or 100% RGDc or 
RGDl mixtures) were used to treat the cells for 1, 4 or 24 h. In order to analyze the endocytic pathway involved, 
media supplemented with 1 μg/mL Hoechst and 200 nM LysoTracker Green were added in each well for 15 min 
at 37 °C, 5%  CO2. To analyze the macropinocytic pathway, cells were incubated with 0.25 mg/mL green labelled 
dextran 70 in media for 1 h at 37 °C, 5%  CO2. After treatment, living cells were washed with PBS and immedi-
ately used for imaging using a confocal microscopy protocol of  ours36. Confocal acquisitions were performed on 
live cells using a Leica TCS SP8 AOBS inverted confocal equipped with an immersion oil objective (63×/1.40/
HCX PL Apo, Leica). For the acquisitions, the confocal settings were as follows: pinhole 1 airy unit, scan speed 
400 Hz unidirectional, format 2048 × 2048 (1× zoom, pixel size 240 nm), format 1,024 × 1,024 (4× zoom, pixel 
size 89 nm). To eliminate any possible crosstalk between channels, images were collected with a sequential scan 
using the following laser lines and mirror settings: 405(100%) 410–483 nm; 488(25%) 495–550 nm; 561(100%) 
nm. Images were processed to enhance brightness using the ImageJ software (https ://rsb.info.nih.gov/ij).
Nanoparticle penetration into U87MG multicellular spheroids. Flow cytometry. U87MG cells were seeded at a 
concentration of 1,000 cells (in 0.1 mL) in a 96-well ultra-low adherent (ULA) plate. The spheroids were grown 
at 37 °C, 5%  CO2 for 10 days, replacing 50 μL of media every 3 days, until the spheroid mass reached a diameter 
of 400 μm. At day 10, 100 µL/well of cell culture media containing 1 mg/mL of rhodamine labeled particles 
(prepared from Pluronic F127-RGD 0% (i.e. nontargeted) or 100% RGDc or RGDl mixtures) was added to 
each well containing a spheroid to obtain a final nanoparticle concentration of 0.5 mg/mL in a total volume of 
200 µL (at least 10 spheroids per experimental condition). After 24 h, the spheroids were washed with PBS and 
incubated with 1 μg/mL Hoechst 33,342 for 5 min at 37 °C, 5%  CO2. Spheroids were then washed with PBS and 
incubated with trypsin/EDTA for 10 min at 37 °C, 5%  CO2, further disaggregated with the help of a pipette 
and the fluorescence arising from Hoechst and rhodamine determined using flow cytometry. Untreated cells 
were used as negative control for autofluorescence and Hoechst fluorescence gradient was used to individuate 
two distinct regions: Hoechst positive cells (bright, Fig. 6A), considered to be at the edge of the spheroids, cells 
below the ones in the edge (middle, Fig. 6A), and Hoechst negative cells, which are considered as those at the 
core(dim, Fig. 6A). The internalization of rhodamine-labeled particles was determined on 10,000 live, individual 
cells using a BD LSRFortessa cytometer (BD Bioscience, San Jose CA, USA) equipped with FACSDiva software 
(v8.0.1). Data were analyzed with FlowJo (vX.0.7, Tree Star, Ashland, OR, USA) after gating single and live events 
in the FSC-A/FSC-H and FSC/SSC windows,  respectively35.
The reason why larger spheroids (average diameter ≈400 µm) were used for flow cytometry vs confocal 
microscopy experiments is threefold: (1) a much higher cell number is needed to run flow experiments, (2) 
larger spheroids are easier to manipulate (i.e. to see and handle) in experiments involving multiple passages, and 
more importantly (3) to obtain a well-defined Hoechst gradient. A quick incubation with Hoechst (for 10 min) is 
enough to create a three-region gradient in 400 µm spheroids; smaller spheroids would encumber this operation 
as Hoechst would quickly penetrate from the surface down to the core.
Confocal microscopy. Spheroids with diameter of about 250 μm were incubated with a final nanoparticle con-
centration of 0.5 mg/mL in cell media (0.2 mL/well). After a 24 h incubation, the spheroids were washed with 
PBS and incubated with 1  μg/mL Hoechst 33,342 and 5  μg/mL CellMask for 5  min at 37  °C, 5%  CO2. The 
spheroids were then washed and used for imaging using a confocal microscope. Confocal acquisitions were 
performed on live cells using a Leica TCS SP8 AOBS inverted confocal equipped with an immersion oil objec-
tive (20×/1.40/HCX PL Apo, Leica). For the acquisitions, the confocal  settings36, were as follows: pinhole 1 airy 
unit, scan speed 400 Hz unidirectional, format 2048 × 2048 (pixel size 280 nm). To eliminate any possible cross-
talk between channels, images were collected with a sequential scan using the following laser lines and mirror 
settings: 405(100%) 410–483 nm; 488(25%) 495–550 nm; 561(100%) nm. Images were processed to enhance 
brightness using the ImageJ software (https ://rsb.info.nih.gov/ij).
For the avoidance of doubt, we decided not to use spheroids larger than 250 µm in diameter for microscopy 
studies (as opposed to the 400 µm spheroids used for flow cytometry) since the transmitted light decreases with 
spheroid size. The use of 250 µm spheroids turned out to be the best compromise between ease of handling and 
light transmission at the core of the sphere.
Results and discussion
Preparation of Pluronic‑VS and conjugation of RGD peptides. We recently developed a robust and 
highly reproducible method to prepare PEGylated nanoparticles via a continuous-flow microfluidic  approach34. 
In brief, the manufacturing procedure consisted of mixing an acetone solution of PLGA with Pluronic F127 in 
water; the precipitation in the form of Pluronic-stabilized PLGA nanoparticles is performed in a cross-shaped 
microfluidic chip (160 μm-wide capillaries), which provides a flow-focused, very reproducible mixing fluidody-
namics. Pluronic F127 was used in its commercially available, OH-terminated form, or after the introduction of 
peptides as terminal groups. To this end, we have used a two-step reaction sequence based on the introduction 
of Michael acceptor groups at the ends of the Pluronic terminal PEG blocks, and their successive Michael-type 
addition with appropriate thiol-containing peptides (Fig. 1A). Firstly, the OH groups of Pluronic F127 were 
reacted with an excess of the bifunctional vinyl sulfone (VS) in the presence of catalytic amounts of NaH, to 
form Pluronic F127-VS. The reaction conditions, derived from a previously published VS-based PEGylation 
 protocol37, rendered a derivatization yield of 63  mol% of the free OH groups (Fig.  1B). The VS group pre-
sents a remarkable reactivity and selectivity towards thiols, making bioconjugation reactions possible with high 
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yield, high purity and in one  step38, as we have recently demonstrated for the functionalization of PEG-VS with 
cysteine-containing  fibrinopeptides39. In the past, we have also shown that the Michael-type addition of thiol-
containing peptides is governed by the cysteine pKa of a cysteine  (thiol40) and we have used this reaction e.g. to 
introduce cysteine-bearing RGD sequences e.g. on hyaluronic  acid41.
In the current work, we conjugated Pluronic F127 with one of two different peptides, namely (1) a fibronec-
tin-derived linear RGD peptide (RGDl, GCG YGR GDSPG), targeting both αvβ3 and α5β1  heterodimers42,43, 
and possibly some others, with typically low affinity values  (IC50 > 100 nM44), and (2) a cyclic RGD peptide 
(RGDc, sequence: RGDFC), which exclusively targets αvβ3 dimers with a high binding affinity  (IC50 = 12 nM/
Ki = 41 ± 0.5 nM for the soluble αvβ3  receptor45). In our hands, we have achieved a quantitative conversion of 
VS groups with both RGD peptides as judged by the complete disappearance of their characteristic 1H NMR 
resonances after only 30 min reaction with both RGD peptides (Fig. 1C). The success of the conjugation of the 
RGD peptides to Pluronic F127-VS was further supported by the presence, in the 1H NMR spectra, of aromatic 
protons from the side chains of tyrosine (Y) and phenylalanine (F), arising from the RGDl and RGDc structures, 
respectively (bottom two spectra in Fig. 1C).
Preparation and characterization of nanoparticles. We have prepared PLGA nanoparticles using a 
continuous-flow microfluidic system (Asia 320 from Syrris Ltd); this automated system allowed to easily and 
reproducibly obtain a library of particles with identical size, bulk composition and PEGylated surface, but differ-
ing both in the identity and in the amount of the decorating peptide (RGDc or RGDl).
The nanoprecipitation conditions used herein were analogous to our previously optimized protocol that 
rendered Pluronic F127/PLGA particles of a desired size, low polydispersity, high stability, good surface coverage 
and a spherical  shape34. For the preparation of nanoparticle formulations exposing varying densities of peptide, 
we used RGD-functionalized and pristine Pluronic F127 mixed in different ratios as surfactants in the nanopre-
cipitation experiments. This led to formulations with a 0, 1, 10, 50 or 100% of Pluronic F127-RGD/–OH ratio 
(assuming the two surfactants to have the same relative ratio on the particle surfaces as in the feed).
We have evaluated the influence of the nature and density of the RGD ligand expressed on the surfactant of the 
nanoparticles on their apparent hydrodynamic size, polydispersity (PDI) and ζ potential (see Fig. 2A–C; Table 1). 
Particles of around 145–160 nm in diameter with remarkably low polydispersity values (< 0.1 in all cases) were 
Figure 2.  Physico-chemical characterization of PLGA nanoparticles as a function of format and concentration 
of Pluronic F127-RGD. The intensity size distribution (A, shown only for the linear RGD peptide) and the 
apparent hydrodynamic size and polydispersity (B) values show that the presence of Pluronic F127-RGD did not 
substantially alter the nanoparticle dimensions, with only slight changes in their ζ potential (C); the data for the 
latter are measured in 10 mM NaCl, for values in deionized water see Table 1. n = 3. (D) The fluorescence of the 
nanoparticles remains unchanged after centrifugation regardless of the surfactant format (100% Pluronic F127-
RGD/–OH mixtures for both RGDc and RGDl) (n = 3).
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obtained. These findings replicate previous results of our group for the PLGA/Pluronic F127 nanoprecipitation 
in cross-shaped  chips34. Of note, particle size and dispersity can be affected by both microfluidic conditions and 
macromolecular  parameters46. In general, neither the format nor the density of the peptide altered much the 
characteristics of the nanoparticles, albeit with a small size increase with 50% RGDl/OH and with 100% RGDc 
or RGDl surfactant mixtures. This is possibly due to a slightly lower capacity of steric stabilization offered by 
surfactants that bear ionic/ionizable or hydrogen donor groups in addition to PEG.
In comparison to other PEGylated PLGA nanoparticle systems in the literature, our apparent hydrodynamic 
sizes are in line with those reported for RGD/RGD peptidomimetic-functionalized nanoparticles (preferential 
delivery of paclitaxel to HUVEC endothelial cells)24, of around 130–150 nm, and considerably smaller than those 
reported for RGDc-decorated ones (targeted delivery of doxorubicin to cancer cell lines)22, of around 400 nm. 
In respect of surface charge all particles exhibited rather high negative ζ-potential values in deionized water, 
with or without peptide (Table 1), which is rather common for aliphatic polyester nanoparticles due to terminal 
carboxylic groups. However, ζ potential values dropped close to zero in 10 mM NaCl (Fig. 2C), which suggests 
a low likelihood of ionic interactions and therefore also of protein adsorption in biological fluids.
A note on particle dimensions: we report values calculated from the DLS intensity distribution; we have previ-
ously  shown34 that in volume distributions obtained through field flow fractionation, the size of these particles 
is slightly higher than 100 nm, and when dried for TEM analysis they look even smaller (see Supplementary 
Fig. 1SI), due to dehydration of the surface PEG chains.
The preparative conditions employed here had previously been optimized to minimize the presence of free 
 surfactant34. It is worth pointing out that any free, integrin-targeting surfactant (possibly competing with the 
RGD-decorated nanoparticles) is assumed to be removed via three rounds of centrifugation/resuspension, which 
at the same time allowed to recover most of the particle mass (typically 90–95% as estimated via DLS count 
 rates48). It is possible to have a (rough) estimate of the density of RGD residues based on the literature values of 
Pluronic F127 interfacial area, and assuming that the peptides do not affect it. According to a study of Alexan-
dridis, the Pluronic F127 surface area may range from 4.3 nm2 per molecule when adsorbed on carbon black 
(from DLS measurements) to 6.8 nm2 when unconstrained in micelles (calculated from the overall micelle radius 
and the average number of association from SANS measurements at 50 °C)49; since our situation is possibly more 
similar to micelles—carbon black is massively more hydrophobic—we have considered a value of about 6  nm2/
molecule. Assuming particles to have a spherical shape and a size of about 150 nm, i.e. an average surface area 
of ~ 70,600  nm2, this would equate to ~ 11,800 Pluronic F127 molecules per particle, corresponding to about 
14,800 peptides per particle (bear in mind the 63% end functionalization of Pluronic F127). Experimentally, the 
amount of exposed peptides was measured via the BCA assay (Table 1, last column from the right), assuming 
nanoparticles to have the same density as bulk PLGA; the experimental peptide surface density scaled with the 
amount of RGD-bearing Pluronic F127 and was in the same order of magnitude as the theoretical prediction, 
but significantly lower than that. We ascribe the discrepancy essentially to the difficult accessibility of most of 
the peptides on the nanoparticle surfaces.
Evaluation of nanoparticle uptake and intracellular sorting. As the next step, we evaluated two 
experimental approaches to obtain traceable particles for use in our biological experiments. The first one con-
sisted of the physical entrapment of small hydrophobic fluorophores  (DiL50 or Nile  Red51) co-dissolved with 
PLGA during nanoprecipitation. We recorded macroscopic agglomeration using DiL (i.e. 2 and 20 µg/mL; see 
Table 1.  Physico-chemical characterization of PLGA nanoparticles prepared via nanoprecipitation from 1, 
10, 50 or 100% Pluronic F127-RGD/–OH mixtures. n.d. non-detectable. a The amount of F127-RGDx was 
measured by BCA assay after centrifugation and removal of unbound Pluronic F127-RGD and concentration 
of particles (×5–×10) by centrifugation, employing the appropriate Pluronic F127-RGDx standards. n = 3 
independent measurements. b The experimental values are calculated from the BCA readouts assuming a 
particle density of 1.24 g/cm3 (value for  PLGA47) and molecular weights of around 13,350 and 13,900 g/mol 
respectively for Pluronic F127-RGDc and for F127-RGDl.
F127-RGDx/F127-OH 
(wt%) Z-average size (nm) PDI
ζ-potential (mV) F127-RGDxa (µg/mg 
particle)
No. of RGD per 
 particleb (exp./theor.)ddH2O 10 mM NaCl
F127-OH
0% 145 ± 3 0.07 ± 0.03 − 30 ± 3 − 4.6 ± 0.2 n.d n.d
F127-RGDc
1% 138 ± 2 0.06 ± 0.03 − 27 ± 2 − 3.9 ± 0.3 n.d n.d./148
10% 138 ± 4 0.05 ± 0.03 − 29 ± 6 − 3.9 ± 0.3 n.d n.d./1,480
50% 148 ± 1 0.09 ± 0.02 − 35 ± 5 − 4.5 ± 0.4 30 ± 5 2,321 ± 500/7,400
100% 145 ± 2 0.09 ± 0.02 − 29 ± 2 − 2.9 ± 0.1 47 ± 2 4,643 ± 200/14,800
F127-RGDl
1% 145 ± 2 0.04 ± 0.01 − 28 ± 4 − 4 ± 0.1 n.d n.d./148
10% 147 ± 2 0.03 ± 0.01 − 33 ± 3 − 4 ± 0.1 10 ± 2 427 ± 190/1,480
50% 154 ± 5 0.08 ± 0.02 − 26 ± 4 − 2.6 ± 0.1 28 ± 4 2,134 ± 380/7,400
100% 160 ± 2 0.06 ± 0.02 − 27 ± 2 − 2.6 ± 0.3 45 ± 8 4,269 ± 760/14,800
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Supplementary Information, Fig. 2SI), which was therefore abandoned. On the contrary, Nile Red up to 50 µg/
mL in the polymer solution did not compromise particle stability and returned brightly fluorescent nanopar-
ticles (Supplementary Fig. 3SI), but in preliminary in vitro experiments rapidly (< 1 min) leaked and stained 
perinuclear regions of A2780 cells (Supplementary Fig. 4SI). Although this phenomenon is often neglected in 
literature, it has been previously reported that a rapid increase in intracellular fluorescence is caused by Nile Red 
leaking out of the particles and associating, due to its lipophilic nature, with serum proteins, thereby leading to 
an overestimation of nanoparticle  uptake52.
As an alternative, rhodamine B was directly conjugated to a carboxylic-terminated PLGA to yield a polymer-
dye conjugate (i.e. PLGA-Rho) that would only be found in the nanoparticles, completely excluding the pos-
sibility of leakage. We used mixtures containing 10, 20 and 50% wt. of PLGA-Rho in unlabeled PLGA (in the 
input acetone solution), obtaining particles with unaltered physico-chemical characteristics (Supplementary 
Fig. 5SI,A–C). A 10% PLGA-Rho/PLGA ratio was sufficient to yield bright and easily detectable nanoparticles 
(unaffected by either the presence of RGD on the surface of particles, their centrifugation or filtration, see Fig. 2D 
and Supplementary Fig. 5SI,D), and this ratio was then employed for all further cell uptake experiments, fol-
lowed via either confocal microscopy or flow cytometry. For these studies, we employed the glioma U87MG 
and the ovarian carcinoma A2780 cell lines, which express integrin heterodimers differing both in amount and 
 type53: the former have very high levels of αvβ3 integrins (~ 2.25 × 105 surface receptors/cell) and still high levels 
of α5β1 integrins (~ 1.25 × 105 surface receptors/cell), the latter minimal levels of αvβ3 and moderate levels of α5β1 
integrins (about half of what reported for U87MG). Therefore, the αvβ3 integrin selective RGDc is expected to 
strongly favor uptake in U87MG (due to their high αvβ3 expression) over A2780; the rather αvβ3/α5β1 unselective 
RGDl should be conducive to a rather similar uptake in the two cell lines.
The 4, 8 and 16 h incubation of cell monolayers with rhodamine-labeled nanoparticles (Fig. 3) showed that:
A. Non-targeted particles had a slow uptake in the two cell lines, slightly more rapid in U87MG.
B. The internalization in A2780 increased when 50% or more Pluronic F127 expressed the RGD peptides, but 
only at 16 h and with no effect of the peptide format.
C. the uptake was significantly enhanced (namely a 2–6 fold increase) in U87MG at any given time point, but 
only with the αvβ3 integrin selective RGDc, and increasingly with its increasing density.
D. RGDl only marginally improved nanoparticle uptake in comparison to non-targeted controls; this may indi-
cate that this Pluronic F127 bound peptide has a low affinity for both integrins, or low for α5β1 and almost 
zero for αvβ3 (although literature seems to exclude this  possibility54). We can further speculate that RGDl 
Figure 3.  (A) Nanoparticle uptake after a 4, 8 or 16 h incubation in cell culture media as a function of the RGD 
format and density on the nanoparticle surface by A2780 ovarian carcinoma cells (top) and U87MG glioma 
cells (bottom). The nanoparticle uptake was followed via flow cytometry by monitoring the fluorescence of the 
nanoparticle hydrophobic core, i.e. rhodamine B-labelled PLGA (PLGA-Rho). Non-targeted nanoparticles (i.e. 
prepared with Pluronic F127-OH) were used as control of non-specific uptake (n = 3). Please note the red line 
is intended to help the reader identify the uptake of non-targeted particles. (B) Cross-correlation between the 
Pluronic F127-RGD mixture used to prepare nanoparticles and the nanoparticle uptake (flow cytometry on live 
cells at 16 h). RGDc = cyclic RGD peptide, specifically targeting αvβ3 heterodimers. RGDl = linear RGD peptide, 
in principle binding to both αvβ3 and α5β1 heterodimers.
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may also promote carrier exocytosis, or that it may not induce integrin clustering, which can account for 
improved (high avidity) binding to  nanoparticles2.
In view of the uptake results, we have selected the U87MG cell line as the most suitable model for further 
experiments, starting with the confirmation that their nanoparticle uptake was in fact mediated by a specific, 
integrin mediated pathway. To this end, cells were pre-incubated for 30 min with several uptake inhibitors or 
competitors, including excess soluble RGD  peptides55,56 or antibodies against specific  heterodimers57, followed 
by a 1 h co-incubation with rhodamine-labelled particles (please refer to Supplementary Information 4SI and 
Supplementary Fig. 6SI.A for cytotoxicity studies of these inhibitors/competitors). The intracellular fluorescence 
was then analyzed via flow cytometry, using cells pre-treated with PBS as positive uptake control (Fig. 4).
The results can be summarized as follows:
1. Nanoparticle uptake was always energy-dependent. A first uptake control was carried out at 4 °C, and at 
that temperature a partial inhibition was recorded for all particles (between 30–50%), more significantly for 
non-targeted ones.
2. The entry mechanism of RGDc-decorated nanoparticles was both RGDc- and αvβ3-dependent. Either an 
excess RGDc in solution or an αvβ3 blocking antibody inhibited approximately 40–50% of their uptake (no 
effect of RDGl or α5β1-blocking antibody). These results match those reported by others for nanoparticles 
exposing cyclic RGD peptides on their  surface23.
3. The entry mechanism of RGDc-decorated nanoparticles was scarcely α5β1-dependent, although still possibly 
involving integrins, and thereby supporting the above hypothesis of low affinity for α5β1. Their cellular uptake 
was not inhibited by incubation with either a α5β1- or α5β1-blocking antibodies, but was reduced with soluble 
RGDl, which suggests an uptake governed by other integrin receptors, rather than by the most abundant 
integrins, i.e. αvβ3 and α5β1.
4. Non-targeted particles likely internalize through a macropinocytosis-dependent pathway, and this may be 
active also for RGDl-decorated ones. The use of EIPA (amiloride, common macropinocytosis inhibitor) 
produced a strong inhibition (about 60%) of the former and a much weaker inhibition (about 20%) of the 
latter. These results were further confirmed by confocal microscopy, using dextran as a macropinocytosis 
probe (Fig. 5B).
5. The uptake of particles may involve integrins also in the absence of RGD peptides: the αvβ3-blocking antibody 
reduced the uptake also of the non-targeted particles (~ 20 to 30%). We currently lack a sound explanation 
of this effect, but one may elaborate on the macropinocytic internalization of these particles (point 4); the 
entry of a number of viruses via membrane ruffling followed by micropinocytosis has been shown to be 
mediated by αvβ358, therefore it may be possible to speculate that—in the absence of other more specific 
binding events—U87MG macropinocytosis may involve αvβ3.
The overall picture seems therefore to be that RGDl-decorated nanoparticles behave rather similarly (macro-
pinocytic uptake with a similar kinetics) to non-targeted ones, although the two particles may differ in the 
involvement of receptors in this process (non-targeted showing signs of αvβ3 involvement).
Finally, we have incubated U87MG cells with the nanoparticle formulations (0 and 100% RGD content) for 
1, 4 or 24 h, followed by the addition of Lysotracker in cell culture media to label (endo)lysosomes. Results in 
Fig. 5A show that RGDc-decorated particles seem to have been taken up faster compared to RGDl-decorated 
Figure 4.  Uptake mechanism in U87MG cells as a function of RGD format on the nanoparticle surface. 
Nanoparticles were prepared from PLGA-Rho in single-emulsifier experiments (i.e. 100% F127-OH or 100% 
F127-RGDx); their uptake was measured by flow cytometry on live cells after pre-treatment for 30 min and 
co-incubation with different agents and nanoparticles for 1 h at 37 °C, and expressed in relation to the control 
experiment performed without inhibitors (i.e. PBS-treated cells). Please note that all cells showed evidence of 
internalization (see Supplementary Fig. 6SI.B), they just differed in the amount of uptake. RGDc = cyclic RGD 
peptide, specifically targeting αvβ3 heterodimers. RGDl = linear RGD peptide, binding to both αvβ3 and α5β1 
heterodimers. Statistical analysis (One-way ANOVA), n = 3.
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or non-targeted counterparts, which again corroborates flow cytometry findings reported in Fig. 4 about the 
preferential uptake of RGDc formulations. After a 4 h exposure, a strong fluorescent signal was already observed 
for RGDc-decorated particles which effectively co-localized with lysosomes, while on the other hand it took 
up to 24 h for the other two formulations to reach similar levels of lysosomal co-localization. Therefore, these 
data confirm that specific targeting of αvβ3 with a RGDc peptide does not only control the levels of uptake of a 
given nanocarrier, but importantly it also shifts the pathway through which the carrier is internalized, in our 
Figure 5.  Uptake of rhodamine-labelled nanoparticles (red) prepared from Pluronic F127-OH, Pluronic 
F127-RGDl or Pluronic F127-RGDc (0 and 100% RGD/OH mixtures) by U87MG glioblastoma cells (confocal 
microscopy on live cells). (A) Nanoparticle intracellular localization over time. Cells were treated for 1 h with 
the three different nanoparticle formulations in cell culture media (0.5 mg/mL) at 37˚C. Nuclei: Hoechst stain 
(blue); lysosomes: Lysotracker (green). Scale bar = 20 μm. (B) Macropinocytosis inhibition. Cells were treated 
for 1 h with the three nanoparticle formulations in cell culture media (0.5 mg/mL) at 37˚C with or without a 
pre-treatment with 5 µM of EIPA for 30 min. Nuclei: Hoechst stain (blue); Macropinosomes: Dextran (green). 
Scale bar = 20 μm.
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case from a preferential macropinocytic entry (for naked particles, also for RGDl) to a receptor-mediated (endo)
lysosomal pathway (for RGDc-functionalized particles). This shift in pathway is relevant for drug delivery in 
Figure 6.  Penetration of rhodamine-labelled PLGA nanoparticles (red) prepared from Pluronic F127-OH, 
Pluronic F127-RGDl or Pluronic F127-RGDc (0 and 100% RGD/OH mixtures) in U87MG multicellular 
spheroids. (A) Flow cytometry analysis: spheroids of about 400 µm in diameter were treated for 24 h with the 
three different nanoparticle formulations in cell culture media (0.5 mg/mL) at 37 ˚C, and then incubated with 
Hoechst (to differentiate between the edge and the inner part of the spheroid) for 10 min before disaggregation 
with trypsin/EDTA and flow cytometry processing. The graphs are representative of 3 independent experiments. 
Statistical analysis (Unpaired t-test), n = 3. (B) Confocal microscopy analysis: spheroids of about 250 µm in 
diameter were treated for 24 h with the three different nanoparticle formulations in cell culture media (0.5 mg/
mL) at 37 ˚C. They were then incubated with Hoechst for 10 min before confocal microscopy analysis. Images 
are representative of 3 independent experiments. Nuclei: Hoechst stain (blue); Cell membranes: CellMask 
(green). Scale bar = 50 μm.
13
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:14505  | https://doi.org/10.1038/s41598-020-71396-x
www.nature.com/scientificreports/
that the processing of carriers via the late endosome/lysosome formation has been proven essential for the 
functional delivery of many biomolecules of interest once released in the cytosolic compartment, for example 
exogenous  mRNA59.
Nanoparticle penetration into U87MG glioma spheroids. The inability of drugs (and drug delivery 
systems) to penetrate and distribute throughout solid tumors remains one of the main limiting factors for suc-
cessful cancer  treatment60,61. Besides, the prediction of the in vivo behavior of a drug carrier proves extremely 
difficult given that all its physico-chemical properties, chiefly its size, overall charge and surface (bio)chemistry, 
can drastically affect its ability to penetrate and accumulate in solid  tumors62. In the last part of this study, we 
have thus evaluated particle penetration into multicellular spheroids, a more complex 3D model that should 
shed further light on the role of integrin-facilitated drug delivery to solid tumors. We have used the U87MG 
cell line as model because of its high integrin expression. Since we have produced nanoparticles differing almost 
exclusively in the surface chemistry (i.e. presence of –OH, –RGDc or –RGDl groups), we assume any difference 
in their behavior correlates with their differential targeting capabilities. In order to produce glioma spheroids 
suitable for penetration studies, we seeded U87MG cells in ultra-low adherent plates for 10 days (i.e. until they 
reached 400 μm in diameter), incubated them with rhodamine labeled nanoparticles, and finally disaggregated 
them and analyzed by flow cytometry. Untreated cells were used as negative control for rhodamine autofluores-
cence and Hoechst was used to differentiate three distinct regions of the spheroid, namely the edge (Hoechst 
highly positive  cells+, labelled as “bright” in Fig. 6A), the middle (Hoechst positive cells, labelled as “middle” in 
Fig. 6A) and the inner part of the spheroids (Hoechst negative cells, labelled as “dim” in Fig. 6A). Our results 
demonstrated no significant differences for RGDl-decorated or non-targeted particles, but an enhanced pen-
etration and accumulation mediated by the RGDc peptide for cells isolated from the periphery of the spheroid 
(namely a threefold increase compared to RGDl or naked particles), but also from those deeper in the spheroid 
(namely a twofold and 1.5  fold increase at middle and inner sections, respectively). These data were further 
corroborated via confocal microscopy analysis of the intact spheroids (250 μm diameter), which qualitatively 
revealed a greater number of nanoparticles penetrating throughout the glioma spheroids, suggesting that the 
enhancement of nanoparticle penetration was possibly due to an improved transcytosis mediated by αvβ3 het-
erodimers (Fig. 6B). Please note that because of the low degree of light penetration (a well-known drawback 
in the confocal microscopy of  spheroids63), it was not possible to observe the cells in the core of the spheroid 
(deeper than 20 μm). Our experimental findings are consistent with the enhanced penetration and accumula-
tion reported for other cRGD-decorated nanosystems in U87MG spheroids, such as c(RGDyK)-functionalized 
micellar  particles64 and polymeric  micelles65,66, as well as for PAMAM-cRGD dendrimer  bioconjugates67,68.
Conclusion
In this study we have evaluated the uptake and intracellular processing of PEGylated PLGA nanoparticles by 
means of their surface decoration with two integrin targeting RGD peptides: a cyclic derivative with preferential 
targeting for αvβ3 integrin heterodimers and a linear derivative with preferential (but not exclusive) targeting 
capabilities for αvβ3 and α5β1 heterodimers. We have produced a library of targeted nanoparticles varying in RGD 
peptide format and surface density, but otherwise having identical physico-chemical properties, to evaluate their 
interactions with A2780 (low integrin expression, α5β1 > αvβ3) and U87MG (high integrin expression, αvβ3 > α5β1) 
cancer cell lines. In this regard, particle decoration with increasing densities of RGDc (but not RGDl) led to an 
enhanced nanoparticle uptake in U87MG cell cultures linked to a αvβ3 integrin specific active internalization 
pathway (as demonstrated by selective inhibition experiments), additionally increasing their localization to 
lysosomes (2D cell culture), as well as their ability to penetrate and accumulate into 3D multicellular spheroids. 
On the contrary, RGDl seemed to be internalized predominantly via a macropinocytic mechanism, leading to 
comparatively lower internalization and penetration. The importance of adequate integrin targeting in the design 
of nanoparticle formulations was also highlighted by the lack of selective accumulation of particles functionalized 
with either of the peptides in A2780 cells. These results encourage further research on the use of RGDc as an 
effective means of improving drug delivery into integrin overexpressing solid tumors, especially for modalities 
that require the (endo)lysosomal pathway for a functional cargo cytosolic release and functioning, e.g. mRNA 
delivery carriers.
Data availability
Data are available from the corresponding authors upon reasonable request and with the permission of 
AstraZeneca.
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